Your browser doesn't support javascript.
loading
The long-term consequences of Corona Virus Disease 2019 patients receiving Chinese herbal medicine treatments in acute phase: A protocol for systematic review and meta-analysis.
Sun, Yi-Ming; Liu, Jia-Yan; Sun, Ran; Zhang, Jie; Xiao, Meng-Lu; Li, Gui-Ping.
Afiliación
  • Sun YM; Chengdu Eighth People's Hospital (Geriatric Hospital of Chengdu Medical College), Chengdu, China.
  • Liu JY; Tianjin Xiangyang Road Community Health Service Center, China.
  • Sun R; Chengdu University of Traditional Chinese Medicine, Chengdu, China.
  • Zhang J; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
  • Xiao ML; Chengdu University of Traditional Chinese Medicine, Chengdu, China.
  • Li GP; First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Medicine (Baltimore) ; 100(29): e26677, 2021 Jul 23.
Article en En | MEDLINE | ID: mdl-34398036
BACKGROUND: In December 2019, the first case of Corona Virus Disease 2019 (COVID-19) associated with severe acute respiratory syndrome coronavirus-2 viral infection was described in Wuhan. Similar to SARS in 2003, COVID-19 also had a lasting impact. Approximately 76% of patients discharged after hospitalization for COVID-19 had neurological manifestations which could persist for 6 months, and some long-term consequences such as the gradual loss of lung function due to pulmonary interstitial fibrosis could have comprehensive effects on daily quality of life for people who were initially believed to have recovered from COVID-19. METHODS AND ANALYSIS: Our comprehensive search strategy developed in consultation with a research librarian. We will search these following electronic databases: PubMed, Cochrane Library, Web of Science, ScienceDirect, Scopus, Google Scholar, Embase, ProQuest, China Science and Technology Journal Database (VIP), China National Knowledge Infrastructure, WANFANG DATA, WHO covid-19 website, and Centers for Disease Control and the Prevention COVID-19 websites of the United States and China. The bias of publication will be confirmed via the P value of Egger test. The quality of studies will be evaluated by the Newcastle-Ottawa Scale. ETHICS AND DISSEMINATION: There are no ethical considerations associated with this study protocol for this systematic review which mainly focuses on the examination of secondary data. On completion of this analysis, we will prepare a manuscript for publication in a peer-reviewed medical journal. PROSPERO REGISTRATION NUMBER: CRD42021258711.
Asunto(s)
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medicamentos Herbarios Chinos / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Diagnostic_studies / Guideline / Systematic_reviews Aspecto: Ethics / Patient_preference Límite: Humans Idioma: En Revista: Medicine (Baltimore) Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Medicamentos Herbarios Chinos / Tratamiento Farmacológico de COVID-19 Tipo de estudio: Diagnostic_studies / Guideline / Systematic_reviews Aspecto: Ethics / Patient_preference Límite: Humans Idioma: En Revista: Medicine (Baltimore) Año: 2021 Tipo del documento: Article País de afiliación: China Pais de publicación: Estados Unidos